AlloVir (ALVR) Competitors $3.06 -0.24 (-7.27%) As of 06/9/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. BMEA, FBRX, CLSD, GANX, KLRS, DTIL, VNRX, IFRX, VTVT, and HOWLShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Biomea Fusion (BMEA), Forte Biosciences (FBRX), Clearside Biomedical (CLSD), Gain Therapeutics (GANX), Allovir (KLRS), Precision BioSciences (DTIL), VolitionRx (VNRX), InflaRx (IFRX), vTv Therapeutics (VTVT), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Biomea Fusion Forte Biosciences Clearside Biomedical Gain Therapeutics Allovir Precision BioSciences VolitionRx InflaRx vTv Therapeutics Werewolf Therapeutics AlloVir (NASDAQ:ALVR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Is ALVR or BMEA more profitable? AlloVir's return on equity of -71.03% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Biomea Fusion N/A -118.90%-93.66% Do institutionals & insiders have more ownership in ALVR or BMEA? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, ALVR or BMEA? AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Do analysts rate ALVR or BMEA? Biomea Fusion has a consensus price target of $21.40, suggesting a potential upside of 745.85%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18 Which has better earnings & valuation, ALVR or BMEA? Biomea Fusion is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.15Biomea FusionN/AN/A-$117.25M-$3.55-0.71 Does the media favor ALVR or BMEA? In the previous week, Biomea Fusion had 2 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Biomea Fusion and 1 mentions for AlloVir. Biomea Fusion's average media sentiment score of 1.06 beat AlloVir's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ALVR or BMEA? Biomea Fusion received 39 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 70.21% of users gave Biomea Fusion an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformAlloVirOutperform Votes2757.45% Underperform Votes2042.55% Biomea FusionOutperform Votes6670.21% Underperform Votes2829.79% SummaryBiomea Fusion beats AlloVir on 11 of the 16 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.43M$3.10B$5.55B$8.67BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-0.1533.8227.2220.17Price / SalesN/A476.37423.71161.98Price / CashN/A168.6838.2534.64Price / Book0.103.497.134.72Net Income-$190.42M-$72.35M$3.23B$247.80M7 Day Performance-0.65%9.39%3.78%2.75%1 Month Performance-12.07%24.23%13.34%9.70%1 Year Performance-83.28%-16.25%32.21%14.51% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$3.06-7.3%N/A-81.9%$15.43MN/A-0.15110News CoverageHigh Trading VolumeBMEABiomea Fusion2.4966 of 5 stars$1.55+7.6%$22.60+1,358.1%-41.3%$58.24MN/A-0.3950Positive NewsFBRXForte Biosciences3.0075 of 5 stars$8.83+3.9%$61.00+590.8%+55,581.8%$58.13MN/A-0.545CLSDClearside Biomedical2.6648 of 5 stars$0.74-2.8%$4.80+548.7%-32.5%$57.50M$3.76M-1.6430Positive NewsGANXGain Therapeutics1.9758 of 5 stars$1.93+9.0%$8.20+324.9%-9.6%$57.05M$50,000.00-1.7520Positive NewsKLRSAllovirN/A$3.00+3.4%N/AN/A$56.11MN/A0.00110News CoverageAnalyst DowngradeDTILPrecision BioSciences4.0474 of 5 stars$5.04+4.3%$47.00+832.5%-57.4%$55.88M$51.14M84.01200VNRXVolitionRx1.8701 of 5 stars$0.53+5.2%$3.75+608.9%-16.3%$54.50M$1.31M-1.4780News CoverageAnalyst ForecastHigh Trading VolumeIFRXInflaRx4.1173 of 5 stars$0.81+0.9%$6.60+714.8%-46.8%$54.38M$129,752.00-0.7560Positive NewsAnalyst RevisionVTVTvTv Therapeutics2.4123 of 5 stars$16.91+6.4%$35.50+109.9%-6.4%$54.03M$17,000.00-3.739HOWLWerewolf Therapeutics3.4857 of 5 stars$1.20-0.8%$8.33+594.4%-59.1%$53.85M$1.14M-0.7840Positive News Related Companies and Tools Related Companies BMEA Alternatives FBRX Alternatives CLSD Alternatives GANX Alternatives KLRS Alternatives DTIL Alternatives VNRX Alternatives IFRX Alternatives VTVT Alternatives HOWL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
